Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and inflammatory diseases. The company’s current pipeline is centered on precision therapies designed to target disease-driving pathways, with programs spanning small molecules and protein therapeutics. Its research includes candidates aimed at key immune system mechanisms such as RIPK2, SLC15A4, IRAK4, and TNFR2, reflecting a broader strategy to address complex immune-mediated conditions. Odyssey Therapeutics serves the healthcare and biotechnology markets, where it contributes to the development of targeted treatments for patients with significant unmet medical needs. Headquartered in Boston, Massachusetts, Odyssey Therapeutics combines discovery and development capabilities across immunology and related therapeutic areas, positioning itself as a specialized player in modern drug development.
$26.16
+$0.54 (+2.11%)
Price from 24 days ago
The business is unprofitable at the operating level (-5415.19% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 33.5% YoY. Margins deteriorated 2391.4pp alongside, both lines moving the wrong way.
ROIC dropped from -326.76% to -438.13%, capital efficiency is deteriorating. Negative free cash flow of -$131M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
-$697K
▼ -33.5% YoY
Net Income (TTM)
-$165M
▼ -14.9% YoY
Op. Margin
23763.99%
▼ -2391.4pp YoY
ROIC
-438.13%
▼ -111.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$132M
▼ -10.5% YoY
Op. Cash Flow (TTM)
-$132M
▼ -10.2% YoY
Net Debt
-$154M
Net Cash Position
Cash & Equiv.
$181M
Continue Research
Odyssey Therapeutics (ODTX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Odyssey Therapeutics scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Odyssey Therapeutics scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 23,764.0% operating margin and a -438.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ODTX's valuation and scores 35/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.